Roivant shares are trading higher after Immunovant announced results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.
Portfolio Pulse from Benzinga Newsdesk
Shares of Roivant Sciences (ROIV) are trading higher following the announcement by Immunovant of positive results from the initial cohort of a Phase 2 clinical trial of batoclimab in patients with Graves' disease, with response rates exceeding 50%.
December 21, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roivant Sciences' stock price is experiencing an uptick due to Immunovant's successful clinical trial results for batoclimab, which could signal future revenue growth for Roivant.
The positive clinical trial results from Immunovant, a company under Roivant Sciences, suggest a potential for successful product development and future revenue streams. This news is likely to be viewed favorably by investors, leading to a short-term increase in ROIV's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90